2024-09-25 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison with S&P 500 (VOO):**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company.  

Compared to the S&P 500 (VOO), JNJ's cumulative return is significantly lower. 

* **JNJ Cumulative Return:** 35.66%
* **VOO Cumulative Return:** 133.37%

**Cumulative Return Difference:** -97.71% 

**Relative Divergence:** 6.72% (This means that JNJ's current performance is at the 6.72% percentile of its historical performance range compared to VOO.)

**2. Recent Price Action:**

* **Closing Price:** 162.35
* **5-day Moving Average:** 164.19
* **20-day Moving Average:** 165.22
* **60-day Moving Average:** 159.18

JNJ's price is currently below its 5-day, 20-day, and 60-day moving averages, suggesting potential downward pressure.

**3. Technical Indicators:**

* **RSI:** 34.05 (This indicates that JNJ is in oversold territory, suggesting potential for a rebound.)
* **PPO:** -0.43 (A negative PPO value indicates a potential downward trend.)
* **Delta_Previous_Relative_Divergence:** -5.05 (This suggests a short-term downward trend.)
* **Expected Return:** 0.0% (The estimated maximum expected return for a 5-year investment is currently 0%.)

**4. Recent Earnings and Outlook:**

| Date         | EPS   | Revenue        |
|--------------|-------|----------------|
| 2024-07-25  | 1.95  | 22.45 B$       |
| 2024-05-01  | 1.35  | 21.38 B$       |
| 2024-02-16  | 1.68  | 21.39 B$       |
| 2023-10-27  | 10.32 | 21.35 B$       |
| 2024-02-16  | 10.32 | 21.35 B$       |

The latest earnings report for Q2 2024 shows that JNJ beat analysts' estimates for both EPS and revenue. The company's pharmaceutical business remains strong, driven by the success of its blockbuster drugs. However, there are concerns about the company's consumer health business, which has faced challenges in recent quarters. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** JNJ's stock has been under pressure in recent months, as investors have become concerned about the company's growth prospects and potential litigation risks. However, the company's strong pharmaceutical business and dividend payouts continue to attract investors.
* **Analyst Opinions:** Analysts are generally neutral on JNJ, with a majority rating it as "hold." Some analysts believe that the company's valuation is attractive, while others are concerned about the company's long-term growth prospects.
* **Performance Highlights:** JNJ's dividend payout ratio has been consistent over the years, and the company is known for its strong cash flow generation. However, the company's earnings growth has slowed in recent years, which has weighed on the stock's performance.

**6. Overall Analysis:**

JNJ is a large, well-established company with a strong track record of profitability. However, the company is facing several challenges, including slowing earnings growth, potential litigation risks, and increased competition in the pharmaceutical industry. While JNJ's valuation appears attractive, its recent underperformance and technical indicators suggest caution. 

**7. Recommendations:**

* **Hold:** Given the current market conditions and JNJ's performance, investors may consider holding their existing positions, but avoid adding to their positions at this time.
* **Long-term Investment:** JNJ remains a solid long-term investment due to its strong cash flow and dividend payouts. However, investors should be prepared for potential volatility in the short term.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions. 
